DK0595798T3 - Bispecifikke heteroantistoffer med dobbelte effektorfunktioner - Google Patents

Bispecifikke heteroantistoffer med dobbelte effektorfunktioner

Info

Publication number
DK0595798T3
DK0595798T3 DK90917241T DK90917241T DK0595798T3 DK 0595798 T3 DK0595798 T3 DK 0595798T3 DK 90917241 T DK90917241 T DK 90917241T DK 90917241 T DK90917241 T DK 90917241T DK 0595798 T3 DK0595798 T3 DK 0595798T3
Authority
DK
Denmark
Prior art keywords
effector cells
molecules
effector functions
target
antigen
Prior art date
Application number
DK90917241T
Other languages
Danish (da)
English (en)
Inventor
Edward D Ball
Paul M Guyre
Michael W Fanger
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Application granted granted Critical
Publication of DK0595798T3 publication Critical patent/DK0595798T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coating Apparatus (AREA)
  • Ink Jet (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK90917241T 1989-10-20 1990-10-18 Bispecifikke heteroantistoffer med dobbelte effektorfunktioner DK0595798T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42454089A 1989-10-20 1989-10-20
PCT/US1990/005981 WO1991005871A1 (en) 1989-10-20 1990-10-18 Bispecific heteroantibodies with dual effector functions

Publications (1)

Publication Number Publication Date
DK0595798T3 true DK0595798T3 (da) 1999-09-27

Family

ID=23682977

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90917241T DK0595798T3 (da) 1989-10-20 1990-10-18 Bispecifikke heteroantistoffer med dobbelte effektorfunktioner

Country Status (9)

Country Link
EP (1) EP0595798B1 (de)
JP (1) JP3360108B2 (de)
AT (1) ATE177152T1 (de)
CA (1) CA2069960C (de)
DE (1) DE69032979T2 (de)
DK (1) DK0595798T3 (de)
ES (1) ES2133139T3 (de)
GR (1) GR3030415T3 (de)
WO (1) WO1991005871A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582996A (en) * 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
WO1994008038A1 (en) * 1992-10-02 1994-04-14 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6365161B1 (en) 1995-06-07 2002-04-02 Medarex, Inc. Therapeutic compounds comprised of anti-FC receptor binding agents
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6821516B1 (en) * 1997-07-18 2004-11-23 I.D.M. Immuno-Designed Molecules Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
WO1999028349A2 (en) 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
WO1999053027A1 (en) * 1998-04-09 1999-10-21 I.D.M. Immuno-Designed Molecules Use of monocytes derived cells and antibodies in a synergic way for optimal induction of immunotherapeutic efficiency
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7235233B2 (en) 2000-09-26 2007-06-26 Crucell Holland B.V. Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts
SI1497438T1 (sl) 2002-04-25 2010-03-31 Crucell Holland Bv Sredstva in postopki za pripravo adenovirusnih vektorjev
CA2833477A1 (en) 2011-04-21 2012-10-26 Seattle Genetics, Inc. Novel binder-drug conjugates (adcs) and their use
DK3086814T3 (da) 2013-12-23 2020-09-14 Bayer Pharma AG Binder-konjugater (adcs) med ksp-inhibitorer
PE20180610A1 (es) 2015-06-22 2018-04-09 Bayer Pharma AG CONJUGADOS DE LIGADOR-PRINCIPIO ACTIVO (ADCs) Y CONJUGADOS DE LIGADOR-PROFARMACO (APDCs) CON GRUPOS ENZIMATICAMENTE ESCINDIBLES
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
JP7022707B2 (ja) 2016-06-15 2022-02-18 バイエル・ファルマ・アクティエンゲゼルシャフト Ｋｓｐ阻害剤および抗ｃｄ１２３抗体を含む特異的抗体－薬物－コンジュゲート（ａｄｃ）
KR20190099250A (ko) 2016-12-21 2019-08-26 바이엘 악티엔게젤샤프트 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물
WO2018114578A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Binder-wirkstoff-konjugate (adcs) mit enzymatisch spaltbaren gruppen
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
GB8802108D0 (en) 1988-01-30 1988-02-24 Univ Dundee Diagnosis & grading of cervical intraepithelial neoplasia(cin)

Also Published As

Publication number Publication date
ES2133139T3 (es) 1999-09-01
GR3030415T3 (en) 1999-09-30
DE69032979T2 (de) 1999-11-04
EP0595798B1 (de) 1999-03-03
WO1991005871A1 (en) 1991-05-02
JP3360108B2 (ja) 2002-12-24
ATE177152T1 (de) 1999-03-15
EP0595798A1 (de) 1994-05-11
CA2069960A1 (en) 1991-04-21
JPH05505595A (ja) 1993-08-19
CA2069960C (en) 2004-03-02
DE69032979D1 (de) 1999-04-08

Similar Documents

Publication Publication Date Title
DK0595798T3 (da) Bispecifikke heteroantistoffer med dobbelte effektorfunktioner
ATE120802T1 (de) Monoklonale antikörper gegen immunglobulin g fc- rezeptoren auf humane mononukleare phagozyten; bifunktionelle antikörper; ziel-spezifische effektorzellen; gezielte makrophagen und immunoassays.
DK154769C (da) Monoklonalt antistof, fremstilling heraf, hybridomacellelinie til anvendelse ved fremstilling heraf samt fremgangsmaader til anvendelse heraf
DE122007000078I1 (de) CTL4A Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendungen
ATE504601T1 (de) Anti-cd3-antikörper zur verwendung zur induzierung von immunsuppression
DK0496818T3 (da) IgA-receptor-specifikt monoklonalt antistof
WO1998023646A3 (en) Binding agents specific for IGA receptor
DE59209079D1 (de) Monoklonale Antikörper gegen humane Pankreas-Inselzellen
DK190287A (da) Monoklonale antistoffer til human-interleukin-2-receptor samt hybridcellelinier til fremstilling deraf
WO1995024481A3 (en) Humanized monoclonal antibodies against human interleukin-4
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
EP0370090A4 (en) Immunogens and biologically active peptides derived from shared sequences from antigens and anti-idiotypic antibodies or antibodies specific for cellular receptors of the antigens